Clinical, Cosmetic and Investigational Dermatology最新文献

{"title":"Burdens of Malignant Melanoma and Projections for 2050 in Asia: Findings from the 2023 Global Burden of Disease Study.","authors":"Chaochao Lu, Chenchang He, Guofang Wang, Shuo Zhao, Heling Huang","doi":"10.2147/CCID.S629052","DOIUrl":"10.2147/CCID.S629052","url":null,"abstract":"<p><strong>Background: </strong>Malignant melanoma(MM) is a significant global health concern, with increasing incidence worldwide. However, comprehensive assessments of its burden in Asia remain limited.</p><p><strong>Methods: </strong>Based on the Global Burden of Disease Study (GBD) data for 2023, an analysis was conducted on the disease burden of MM across 48 countries in Asia from 1990 to 2023. The trends in the disease burden of MM were assessed using the Estimated Annual Percentage Change (EAPC). Furthermore, the Bayesian Age-Period-Cohort (BAPC) model was employed to predict the future burden of MM to 2050.</p><p><strong>Results: </strong>From 1990 to 2023, age-standardized incidence rates (ASIR) increased across most of Asia, with the most pronounced positive EAPC values observed in low- and middle-SDI regions. In contrast, high-SDI areas exhibited stable incidence rates but declining mortality and disability-adjusted life year (DALY) rates. The epicenter of the burden shifted from affluent nations to rapidly developing economies; by 2023, East Asia reported the highest absolute case numbers and prevalence. The age distribution has shifted from the 45-64 age group to those aged 65 years and older, with individuals aged 75 and above dominating both prevalence and mortality rates in East Asia. Key drivers of these trends include cumulative UV exposure, lifestyle changes, and disparities in diagnosis and treatment. The BAPC forecasts for East Asia from 2024 to 2050 predict continued increases in ASIR and prevalence, stabilization of mortality rates, and modest declines in DALYs; however, uncertainty intervals widen as the forecast horizon extends.</p><p><strong>Conclusion: </strong>Asia faces a dual challenge: rising incidence and a progressive eastward/southward burden shift to lower‑SDI countries. Effective responses require equitable, context‑specific strategies combining sun‑safety campaigns, early detection, advanced diagnostics, and affordable treatments across socioeconomic strata. Strengthening prevention, healthcare infrastructure, and surveillance is essential to reduce the long‑term human and economic impact of melanoma in the region.</p>","PeriodicalId":10447,"journal":{"name":"Clinical, Cosmetic and Investigational Dermatology","volume":"19 ","pages":"629052"},"PeriodicalIF":2.5,"publicationDate":"2026-09-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13557228/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148918613","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Moulin's Linear Atrophoderma: Two Case Reports and Literature Review.","authors":"Jiaxin Meng, Lingzhu Liao, Shi Wu, Yong He, Yunfeng Hu, Saijun Liu","doi":"10.2147/CCID.S592349","DOIUrl":"10.2147/CCID.S592349","url":null,"abstract":"<p><p>Moulin's linear atrophoderma (LAM) is a rare acquired pigmentary atrophic dermatosis distributed along Blaschko's lines, with an unclear etiology and poorly understood pathogenesis. This report presents two cases of LAM. Both patients were male, with onset during adolescence. Notably, one patient exhibited elevated antinuclear antibody (ANA) levels (1:320). Histopathological examination of both cases revealed a generally normal or mildly hyperplastic epidermis, hyperpigmentation of the basal layer, and a mixed inflammatory cell infiltrate (predominantly lymphocytes) in the dermis. Based on their clinical presentation and histopathological findings, both patients were diagnosed with LAM.</p>","PeriodicalId":10447,"journal":{"name":"Clinical, Cosmetic and Investigational Dermatology","volume":"19 ","pages":"592349"},"PeriodicalIF":2.5,"publicationDate":"2026-09-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13557156/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148918716","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Dupilumab Combined with Topical 5% Minoxidil for Severe Alopecia Areata in a 2-Year-Old Child with Type 2 Immune Features: A Case Report.","authors":"Yu-Hao Song, Ying-Qi Zhang, Bin Zhang, Qiang Zhang, Ri-Ga Wu","doi":"10.2147/CCID.S617906","DOIUrl":"10.2147/CCID.S617906","url":null,"abstract":"<p><strong>Background: </strong>Severe alopecia areata (AA) in very young children is difficult to manage because evidence-based treatment options are limited and currently approved Janus kinase (JAK) inhibitor therapies do not cover children younger than 12 years. Type 2 immune activity may contribute to AA in a subset of patients with atopic features, providing a rationale for considering dupilumab.</p><p><strong>Case presentation: </strong>A 2-year-and-5-month-old girl with a 2-year history of progressive scalp hair loss presented with severe diffuse AA (Severity of Alopecia Tool [SALT] score, 85%). She had a history of eczema, a family history of eczema, and mildly elevated total serum immunoglobulin E. Baseline dermoscopy showed sparse vellus hairs and occasional black dots without prominent perifollicular erythema or vascular changes. Previous topical and systemic treatments had produced minimal improvement.</p><p><strong>Intervention and outcome: </strong>After discussion with the family regarding the off-label nature, uncertainties, potential risks, and alternatives, subcutaneous dupilumab was initiated together with topical 5% minoxidil. Initial regrowth was observed at week 7, followed by progressive improvement; the SALT score decreased to approximately 9% by week 37. No treatment-related adverse events were reported during 9 months of follow-up.</p><p><strong>Conclusion: </strong>This case adds to emerging evidence that dupilumab may be considered in carefully selected pediatric patients with severe, treatment-refractory AA and features suggestive of type 2 immune involvement. Because minoxidil was continued concomitantly, baseline inflammatory activity was limited, and spontaneous regrowth cannot be excluded, the clinical improvement cannot be attributed to dupilumab alone.</p>","PeriodicalId":10447,"journal":{"name":"Clinical, Cosmetic and Investigational Dermatology","volume":"19 ","pages":"617906"},"PeriodicalIF":2.5,"publicationDate":"2026-09-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13557175/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148918603","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Pemphigus Erythematosus Treated with JAK1 Inhibitor Upadacitinib: A Case Report and Brief Literature Review.","authors":"Hou-Man Lo, Xin-Ran Song, Qian Zhang, Jing Su, Wei-Wei Li, Dong-Ming Li, Wen-Hui Wang","doi":"10.2147/CCID.S637371","DOIUrl":"10.2147/CCID.S637371","url":null,"abstract":"<p><p>Pemphigus erythematosus (PE) is a rare subtype of pemphigus, and management may be particularly challenging when prolonged systemic corticosteroid exposure is undesirable. We report a 31-year-old woman with PE and concomitant erosive gastritis who received off-label treatment with the selective Janus kinase 1 (JAK1) inhibitor upadacitinib after continued systemic corticosteroid therapy was considered unsuitable. Despite initial treatment with methylprednisolone plus upadacitinib 15 mg daily, the disease progressed rapidly, prompting escalation of upadacitinib to 30 mg daily. New blister formation ceased within 1 week, methylprednisolone was discontinued by week 4, complete clinical resolution was achieved by week 8, and anti-desmoglein 1 antibody levels normalized by week 11. After disease control had been achieved, upadacitinib was reduced to 15 mg daily and discontinued after 8 months, with sustained remission and no treatment-related adverse events during 1 year of follow-up. In the context of limited published experience with JAK inhibitors in pemphigus, this single case provides preliminary evidence that upadacitinib may warrant further investigation as a potential corticosteroid-sparing option for selected patients with PE and treatment-limiting comorbidities.</p>","PeriodicalId":10447,"journal":{"name":"Clinical, Cosmetic and Investigational Dermatology","volume":"19 ","pages":"637371"},"PeriodicalIF":2.5,"publicationDate":"2026-09-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13552389/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148911083","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Diagnosis of Telangiectasia Macularis Eruptiva Perstans Using Dermoscopy and Reflectance Confocal Microscopy: A Case Report.","authors":"Jie Zhou, Shichen Jiang, Weimian Xiao","doi":"10.2147/CCID.S573062","DOIUrl":"10.2147/CCID.S573062","url":null,"abstract":"<p><p>Telangiectasia macularis eruptiva perstans (TMEP) is a rare subtype of cutaneous mastocytosis with a favorable prognosis and typically no systemic involvement. Although mast cell infiltration is a key histopathological feature, the cost and invasiveness of biopsy can deter patients from undergoing the procedure. Non-invasive techniques such as dermoscopy and reflectance confocal microscopy (RCM) can be helpful in the diagnosis of TMEP. However, the dermoscopic and RCM features of TMEP have not been fully elucidated. Herein, we report a case of TMEP and describe its dermoscopic and RCM features.</p>","PeriodicalId":10447,"journal":{"name":"Clinical, Cosmetic and Investigational Dermatology","volume":"19 ","pages":"573062"},"PeriodicalIF":2.5,"publicationDate":"2026-09-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13555329/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148918639","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Atypical Facial and Scalp Lupus Erythematosus Tumidus: Diagnostic Challenges from Long-Term Misdiagnosis and Conflicting Histopathology.","authors":"Menglin Li, Tao Guo, Junling Zhang","doi":"10.2147/CCID.S636190","DOIUrl":"10.2147/CCID.S636190","url":null,"abstract":"<p><strong>Background: </strong>Lupus erythematosus tumidus (LET) is a rare photosensitive skin lupus subtype. Its erythematous swelling easily mimics erysipelas, cellulitis or herpes zoster, leading to frequent misdiagnosis. Atypical cases complicated by interface dermatitis and patient self-medication create prominent differential diagnostic difficulties.</p><p><strong>Case presentation: </strong>A 58-year-old woman had scalp and facial erythema swelling for 1 year, worsened over 4 days. She was repeatedly misdiagnosed with bacterial infectious skin diseases and given ineffective antibiotics. Before admission, she took herbal decoctions and received bloodletting acupuncture by herself, aggravating facial edema. Examination showed infiltrative erythema and scalp alopecia. Full autoantibody, complement and routine lab tests were nearly normal. Cheek biopsy showed typical LET mucin deposition and periadnexal lymphocytic infiltration, while scalp biopsy unexpectedly revealed focal basal liquefaction degeneration. The final diagnosis of atypical LET was made after comprehensive clinicopathological evaluation. Combined hydroxychloroquine and methylprednisolone therapy induced obvious lesion remission within 6 months of follow-up.</p><p><strong>Conclusion: </strong>This atypical LET case illustrates key differential diagnostic traps caused by long-term misdiagnosis and conflicting pathological findings. Unsupervised herbal treatment and blood-letting acupuncture disturbs clinical manifestations and delays formal therapy. For patients presenting with facial edematous erythema accompanied by atypical epidermal pathological changes, comprehensive serological screening and thorough histopathological examination are warranted. Early clinicopathological combined diagnosis, antimalarial drugs and strict sun protection help avoid misdiagnosis and recurrence.</p>","PeriodicalId":10447,"journal":{"name":"Clinical, Cosmetic and Investigational Dermatology","volume":"19 ","pages":"636190"},"PeriodicalIF":2.5,"publicationDate":"2026-09-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13549298/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148905229","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Safety and Predictors of Clinically Significant Adverse Effects of Isotretinoin in Acne Vulgaris: A Retrospective Cohort Study from Saudi Arabia.","authors":"Saeed A Al-Qahtani, Amal A Alqahtani, Hadi Almansour, Moaddey Alfarhan, Amani Khardali, Mohammad Jaffar Sadiq Mantargi, Ali Mohamed Alshabi, Saleh Alghamdi, Mohammad Algarni","doi":"10.2147/CCID.S624648","DOIUrl":"10.2147/CCID.S624648","url":null,"abstract":"<p><strong>Purpose: </strong>Isotretinoin remains the most effective treatment for moderate-to-severe acne vulgaris; however, its use is frequently associated with mucocutaneous and metabolic adverse effects that may necessitate active clinical intervention. Data evaluating predictors of clinically significant toxicity in Saudi populations remain limited.</p><p><strong>Patients and methods: </strong>A retrospective cohort study was conducted at a tertiary academic hospital in Saudi Arabia. Electronic medical records of patients with acne vulgaris treated with isotretinoin between January 2020 and December 2024 were reviewed. Demographic variables, acne severity, isotretinoin dosing characteristics, laboratory findings, adverse effects, management strategies, and treatment outcomes were extracted. Multivariable regression analysis was performed to identify predictors of adverse effects requiring clinical intervention.</p><p><strong>Results: </strong>A total of 444 patients were included. Most participants were aged 21-30 years (60.4%), and females represented 50.9% of the cohort. Clinical intervention was required in 70.7% of patients, including supportive care, treatment reduction and dose discontinuation to manage isotretinoin-related adverse effects. Mucocutaneous adverse effects, particularly cheilitis and xerosis, were the most frequently documented complications. Laboratory abnormalities were observed less frequently, although elevated LDL levels were identified in 9.9% of patients, followed by elevated total cholesterol (7.2%) and triglycerides (4.5%). Elevated liver enzymes were relatively uncommon (AST 4.1%, ALT 3.2%). Higher cumulative dose, dose escalation during therapy, and higher maximum dose significantly increased the likelihood of requiring clinical intervention. Female sex and higher body weight were associated with lower odds of intervention. Major improvement was achieved in 37.4%, complete clearance in 28.8%, giving a combined rate of 66.2% while recurrence after discontinuation occurred in 19.4%.</p><p><strong>Conclusion: </strong>Isotretinoin, proved efficacious clinically in the management of acne vulgaris, however was identified to be associated with high number of adverse effects which require active management. Multivariable regression identified that the increasing dose and cumulative dose were the most influential determinants of the drug therapy. Particularly, lipid abnormalities (elevated LDL) were clinically relevant for the included cohort of patients. The outcomes therefore emphasize the need for a personalised approach to dosing along with continuous monitoring to achieve the optimal results.</p>","PeriodicalId":10447,"journal":{"name":"Clinical, Cosmetic and Investigational Dermatology","volume":"19 ","pages":"624648"},"PeriodicalIF":2.5,"publicationDate":"2026-09-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13563201/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148955010","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Tofacitinib as a Promising Therapeutic Option for Vitiligo: A Systematic Review.","authors":"Mansooreh Ahmadkhani, Tahereh Dara, Mohsen Zabihi, Fatemeh Saghafi","doi":"10.2147/CCID.S628682","DOIUrl":"10.2147/CCID.S628682","url":null,"abstract":"<p><strong>Background: </strong>Vitiligo is a chronic autoimmune disease characterized by depigmented patches on the skin. Despite the availability of several therapeutic options, treatment outcomes remain variable, particularly in extensive or refractory disease. Tofacitinib, a Janus kinase (JAK) inhibitor, has emerged as a potential therapeutic option for vitiligo. Here we aimed to review the existing evidence on the efficacy and safety of tofacitinib for the treatment of vitiligo.</p><p><strong>Methods: </strong>A comprehensive search was conducted in PubMed, Scopus, and Web of Science identify English-language studies evaluating the use of tofacitinib in vitiligo patients.</p><p><strong>Results: </strong>Twenty-five studies evaluating oral and topical tofacitinib were reviewed. Reported repigmentation rates ranged from 14.4% to 90%, with several studies also demonstrating improvements in disease activity scores. Most adverse events were mild and infrequent. However, the available evidence is derived predominantly from case reports, case series, and small observational studies, and many patients received concomitant therapies such as phototherapy, limiting the interpretation of treatment efficacy.</p><p><strong>Conclusion: </strong>Current evidence suggests that tofacitinib may represent a promising therapeutic option for vitiligo. However, the available evidence remains limited by the predominance of small uncontrolled studies, heterogeneous treatment protocols, and concomitant therapies. Larger prospective controlled studies are needed to better establish its efficacy, long-term safety, and role within current vitiligo treatment strategies.</p>","PeriodicalId":10447,"journal":{"name":"Clinical, Cosmetic and Investigational Dermatology","volume":"19 ","pages":"628682"},"PeriodicalIF":2.5,"publicationDate":"2026-09-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13549176/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148905307","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Thematic Evolution and Diversification of Bullous Pemphigoid Research: A Bibliometric Analysis, 1959-2025.","authors":"Ming-Chi Lu, Meng-Chi Chiu, Malcolm Koo","doi":"10.2147/CCID.S622840","DOIUrl":"10.2147/CCID.S622840","url":null,"abstract":"<p><strong>Background: </strong>Bullous pemphigoid research spans autoantigen and basement membrane biology, diagnosis, comorbidity, inflammatory pathways, and treatment, but its long-term conceptual development has not been mapped.</p><p><strong>Methods: </strong>English-language articles and reviews indexed in the Science Citation Index Expanded through December 31, 2025, were retrieved from title, author-keyword, and abstract fields. Records underwent AI-assisted first-pass screening followed by human review. Bibliometrix and VOSviewer were used for parameter-tested author-keyword clustering and a full-corpus title-term sensitivity analysis.</p><p><strong>Results: </strong>Of 3,471 screened records, 2,121 were eligible. Annual output accelerated after 2015 and exceeded 100 publications in 2022, 2023, and 2025. Author keywords were available for 55.1% of publications. The selected network contained 112 keywords, 889 links, and eight clusters. Among 924 keyword-mappable publications, autoantigens, autoantibodies, and basement membrane zone biology declined from 51.9% in 1959-1998 to 14.6% in 2021-2025. Therapeutic management and clinical outcomes increased from 7.7% to 37.8%, epidemiology and comorbidities from 1.9% to 20.8%, dipeptidyl peptidase-4 inhibitor-associated bullous pemphigoid from 0% to 12.7%, and immune checkpoint inhibitor-associated bullous pemphigoid from 0% to 10.8%. Diagnosis and related autoimmune blistering diseases peaked at 50.0% in 1999-2013 before declining to 24.3%. Inflammatory and immune effector mechanisms showed no statistically significant period variation after multiplicity adjustment. The title-term analysis recovered the major domains.</p><p><strong>Conclusion: </strong>Bullous pemphigoid research diversified from structural, immunological, and diagnostic foundations toward treatment, clinical outcomes, comorbidity, and medication-associated disease. Although author-keyword availability was incomplete and varied substantially over time, the findings provide a longitudinal map of the field, with temporal estimates reflecting relative prominence within keyword-mappable publications.</p>","PeriodicalId":10447,"journal":{"name":"Clinical, Cosmetic and Investigational Dermatology","volume":"19 ","pages":"622840"},"PeriodicalIF":2.5,"publicationDate":"2026-09-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13546639/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148900361","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Dupilumab for Drug-Induced Bullous Pemphigoid: A Case Series and Literature Review.","authors":"Nawara Sakpuwadol, Suthinee Rutnin, Wimolsiri Iamsumang, Kumutnart Chanprapaph","doi":"10.2147/CCID.S619965","DOIUrl":"10.2147/CCID.S619965","url":null,"abstract":"<p><p>Drug-induced bullous pemphigoid (BP) is an increasingly recognized variant of BP with unique challenges in management, particularly when patients require continuation of the offending medication or are contraindicated to conventional immunosuppressive therapies. We report 4 patients with drug-induced BP, three associated with dipeptidyl peptidase-4 inhibitors and one with immune checkpoint inhibitor, successfully treated with dupilumab. All four patients had failed or were intolerant to conventional therapies. Following dupilumab initiation, all patients experienced significant improvement in pruritus within 2 weeks. Complete remission was achieved in 3 patients within 1-5 months of treatment and one patient had stable disease, enabling him to resume pembrolizumab therapy for esophageal cancer while on dupilumab. No significant adverse effects were reported during treatment periods. Our findings, supported by a literature review, suggest that dupilumab demonstrates promising efficacy and safety in treating drug-induced BP, with rapid improvement in pruritus and resolution of skin lesions. It may offer a valuable therapeutic alternative as a steroid sparing agent for elderly patients with multiple comorbidities and provides the potential to continue necessary medications (eg, cancer therapy) that may have triggered BP.</p>","PeriodicalId":10447,"journal":{"name":"Clinical, Cosmetic and Investigational Dermatology","volume":"19 ","pages":"619965"},"PeriodicalIF":2.5,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13546065/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148896546","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}